Plasminogen activator inhibitor-1 (PAI-1) is the main physiological inhibitor of plasminogen
activators (PAs) and is therefore an important inhibitor of the plasminogen/plasmin system …

Angiogenesis is a process associated with the migration and proliferation of endothelial
cells (EC) to form new blood vessels. It is involved in various physiological and …

Plasminogen activator inhibitor 1 (PAI-1) is a member of the serine protease inhibitor
(serpin) superfamily. PAI-1 is the principal inhibitor of the plasminogen activators, tissue …

Diseases originating from altered energy homeostasis including obesity, and type 2
diabetes are rapidly increasing worldwide. Research in the last few decades on animal …

Chronic kidney disease is characterized by progressive scarring that results in loss of
normal tissue in the kidney and eventually end-stage kidney disease. Interstitial fibrosis and …

Background Plasminogen activator inhibitor‐1 (PAI‐1), the main inhibitor of fibrinolysis, is
frequently elevated in obesity and could potentially mediate the risk of venous …

Thrombin activatable fibrinolysis inhibitor (TAFI), a proenzyme, is converted to a potent
attenuator of the fibrinolytic system upon activation by thrombin, plasmin, or the thrombin …

Fibrosis is the abnormal accumulation of extracellular matrix proteins such as collagen and
fibronectin. Aging, injury, infections, and inflammation can cause different types of tissue …

Atherosclerosis is the major cause of coronary artery disease (CAD) which includes
unstable angina, myocardial infarction, and heart failure. The onset of atherogenesis, a …

Background Obesity is a well-established risk factor for venous thromboembolism (VTE).
However, data on the proportion of incident VTEs attributed to overweight and obesity in the …